|Bid||1.6000 x 0|
|Ask||1.9000 x 0|
|Day's range||1.7000 - 1.7000|
|52-week range||1.3100 - 2.5000|
|Beta (5Y monthly)||0.57|
|PE ratio (TTM)||N/A|
|Earnings date||21 Mar 2023 - 27 Mar 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
On a positive note, Medtronic (MDT) registers organic growth in the Cardiovascular and Neuroscience segments.
Medtronic (NYSE: MDT) may be a leader in the medical device space, but its sluggish 1.3% revenue growth over the past three years has not kept pace with the 5% growth of the medical device market. Medtronic's Surgical Innovations segment achieved robust growth over the past year. Its 9% revenue growth overshadowed the 2%-3% revenue growth from the Cardiovascular and Neuroscience segments.
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...